CD274 and neoplasm: Positive PD-L1 expression on immune cells was associated with worse survival in ICSlow tumors (5-year OS for ICSlow/PD-L1IClow tumors was 17% vs. 0% for ICSlow/PD-L1IChigh, P=0.026) but not in ICShigh tumor subgroup (P=0.563).